Evidence map›Paper›PMID 37856008›Full record

ArticleEJNMMI radiopharmacy and chemistry2023

TrisOxine abiotic siderophores for technetium complexation: radiolabeling and biodistribution studies.

Julien Leenhardt, Alexandre Biguet Petit Jean, Florian Raes, Emilien N'Guessan, Marlène Debiossat, Clémence André, Sandrine Bacot, Mitra Ahmadi, Nicolas de Leiris, Loïc Djaileb and 5 more

Open access · goldAbstract read
In one paragraph

Article in EJNMMI radiopharmacy and chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.2field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Julien LeenhardtUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France. jleenhardt@chu-grenoble.fr.ORCID http://orcid.org/0000-0002-2863-5011
Alexandre Biguet Petit JeanCHU Saint-Etienne, Radiopharmacy/Nuclear Medicine, Saint-Etienne, France.
Florian RaesUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Emilien N'GuessanUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Marlène DebiossatUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Clémence AndréUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Sandrine BacotUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Mitra AhmadiUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Nicolas de LeirisUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Loïc DjailebUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Catherine GhezziUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Marie-Dominique BrunetUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Alexis BroisatUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Pascale PerretUniversité Grenoble Alpes, INSERM, CHU Grenoble Alpes, LRB, 38000, Grenoble, France.
Amaury du Moulinet d'HardemareUniversité Grenoble Alpes, Department of Molecular Chemistry, Saint Martin d'Hères, France. amaury.d-hardemare@univ-grenoble-alpes.fr.
Inserm · FRCentre Hospitalier Universitaire de Saint-Étienne · FRUniversité Grenoble Alpes · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDespite the development of positron emission tomography (PET), single photon emission computed tomography (SPECT) still accounts for around 80% of all examinations performed in nuclear medicine departments. The search for new radiotracers or chelating agents for Technetium-99m is therefore still ongoing. O-TRENSOX and O-TRENOX two synthetic siderophores would be good candidates for this purpose as they are hexadentate ligands based on the very versatile and efficient 8-hydroxyquinoline chelating subunit. First, the radiolabeling of O-TRENOX and O-TRENSOX with

resultsThe radiolabeling studies showed a rapid and efficient complexation of

conclusionsThese encouraging results allow us to consider the O-TRENOX/

Indexed as

BiodistributionChelatesNano SPECT/CT imagingOxidation stateRadiochemical purityRadiochemistrySiderophoresTechnetium-99m

Identifiers

PMID37856008
PMCPMC10587049
OpenAlexW4387765455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.